RobertAlanBaiocchiMDPhD

PubMed

• Corrigendum to 'Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States' [Clinical Lymphoma, Myeloma, and L...
  Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, Amin H Nassar, Elio Adib
  Clinical Lymphoma, Myeloma & Leukemia. 2024-12-01
• A retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter?
  Gretchen A McNally, Connor M Aossey, Tracy Wiczer, Loraine T Sinnott, Mark Lustberg
  Leukemia & Lymphoma. 2024-08-01
• 1 citations
  Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.
  Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, Amin H Nassar, Elio Adib
  Clinical Lymphoma, Myeloma & Leukemia. 2024-08-01

Journal Articles

• ROR1 targeted delivery of OSU-2S, a non-immunosuppressive FTY720 derivative exerts potent cytotoxicity in mantle cell lymphoma in-vitro and in-vivo  
  Mani R, Chiang CL, Frissora FW, Yan R, Mo X, Baskar S, Rader C, Phelps MA, Chen CS, Lee RJ, Byrd JC, Baiocchi R, Lee LJ, Muthusamy N, Exp Hematol, 1/1/2015
• AIDS Malignancy Consortium AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma  
  Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, Ratner L, Wagner-Johnston N, Kaplan L, Blood, 1/1/2015
• The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and ref...  
  Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA, Br J Haematol, 1/1/2015
• A Phase I study of Vorinostat maintenance after autologous transplant in high risk lymphoma  
  Hofmeister CC, Williams N, Geyer S, Hade EM, Bowers MA, Earl CT, Vaughn J, Bingman A, Humphries K, Lozanski G, Baiocchi RA, Jaglowski SM, Blum K, Porcu P, Flynn J, Pen..., Leuk Lymphoma, 1/1/2015
• Targeting the PI3-Kinase (PI3K), AKT, mTOR Axis in Lymphoma  
  Blachly JS, Baiocchi RA, Br J J Haematol, 1/1/2014
• Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma  
  Blachly JS, Baiocchi RA, Br J Haematol, 1/1/2014
• Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin’s lymphoma  
  Jones, JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi RA, Benson DM, Blum KA, Christian B, Flynn J, Penza S. Porcu P. Grever MR, Byrd JC, Am J Hematol, 1/1/2014
• Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors  
  Shilo K, Wu X, Sharma S, Welliver M, Duan W, Villalona-Calero M, Fukuoka J, Sif S, Baiocchi RA, Hitchcock CL, Zhao W, Otterson GA, Diagn Pathol, 1/10/2013
• Protein arginine methyltransferase 5 (PRMT5) inhibition induces death of lymphoma cells through reactivation of the retinoblastoma tumor suppressor pathway and silenci...  
  Chung J, Karkhanis V, Tae S, Yan F, Smith P, Ayers L, Agostinelli C, Sileri S, Denis G, Baiocchi RA, Sif S, J Biol Chem, 1/6/2013
• Association of Pre-Transplantation PET/CT and Outcome in Mantle Cell Lymphoma  
  Cohen, JB, Hall NC, Ruppert AS, Jones JA, Porcu P, Baiocchi RA, Christian BA, Penza S, Benson DM, Jr., Flynn JM, Andritsos LA, Devine SM, Blum KA, Bone Marrow Transplantation, 1/1/2013
• Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia  
  Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi RA, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JM, Leuk Res, 1/1/2013
• PRMT5 is upregulated in malignant and metastatic melanoma and deregulates expression of MITF and p27 Kip1  
  Nicholas C. Yang J, Peters SB, Bill MA, Baiocchi RA, Yang F, Sif S, Tae S, Gaudia E, Wu X, Grever MR, Young GS, Lesinski GB, PLoS ONE, 1/1/2013
• Guidelines for the use and interpretation of assays for monitoring autophagy  
  Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn AJ, Ait-Mohamed O, Ait- Si-Ali ..., Autophagy, 1/1/2012
• Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol  
  Alinari L, Prince CJ, Edwards RB, Towns WH, Mani R, Lehman A, Zhang X, Jarjoura D, Pan L, Kinghorn D, Grever MR, Baiocchi RA, Lucas DM, Clin. Cancer Res, 1/1/2012
• Lymphomatoid Granulomatosis Presenting with Gingival Involvement in an Immune Competent Elderly Male  
  Alinari L, Pant S, Allen C, Baiocchi RA, Head and Neck Pathology, 1/1/2012
• Synthesis, Biological Evaluation, and Radio iodination of Halogenated closo-Carboranylthymidine Analogues (1)  
  Tiwari R, Toppino A, Agarwal HK, Huo T, Byun Y, Gallucci J, Hasabelnaby S, Khalil A, Goudah A, Baiocchi RA, Darby MV, Barth RF, Tjarks W, Inorg Chem, 1/1/2012
• The PD-1 / PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel, monoclonal anti-PD-1 antibody  
  Benson Jr DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield C, Porcu P, Devine SM, Rotem-Yehudar R, Lozans..., Blood, 1/1/2010
• Phase 2 trials of rituximab and Bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma  
  Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd JC, Blum KA, Cancer, 1/1/2010
• A dose-finding, pharmacokinetic and pharmacodynamics study of a novel schedule of flavopiridol in patients with advanced solid tumors  
  Ramaswamy B, Phelps MA, Baiocchi RA, Bekaii-Saab T, Ni W, Lai JP, Wolfson A, Lustberg ME, Wei L, Wilkins D, Campbell A, Arbogast D, Doyle A, Byrd JC, Grever MR, Shah MH, Invest New Drugs, 1/1/2010
• Expression of viral protein, DNA, and host microRNA of cell lines and tumor tissues after different fixation methods  
  Yan F, Wu X, Crawford M, Duan W, Wilding E.E., Chen L, Gao L, Otterson D, Nana-Sinkam P, Villalona MA, Otterson GA, Baiocchi R.A, Methods, 1/1/2010
• Eculizumab therapy in an adult with plasma exchange refractory atypical hemolytic uremic syndrome  
  Prescott H, Wu H.M., Cataland S.R., and Baiocchi R.A, American Journal of Hematology, 1/1/2010
• Phase I trial of low dose decitabine targeting DNA hyper methylation in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma: dose-limiting myelosuppres...  
  Blum KA, Liu Z, Lucas DM, Chen P, Xie Z, Baiocchi RA, Benson DM, Devine SM, Jones J, Andritsos L, Flynn J, Plass C, Marcucci G, Chan KK, Grever MR, Byrd JC, Br J Haematol, 1/1/2010
• Novel Sp1/NFkB/HDAC/miR-29b Regulatory Network in KIT-driven  
  Liu S, Wu L-C, Pang J, Santhanam R, Schwind S, Wu Y-Z, Hickey C, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, Eiring AM, Briesewitz..., Myeloid Leukemia. Cancer Cell, 1/1/2010
• Methylation of histone H3 and H4 by PRMT5 regulate ribosomal RNA gene transcription  
  Majumder S, Alinari L, Roy S, Miller T, Datta J, Sif S, Baiocchi RA, Jacob ST, Journal of Cellular Biochemistry, 1/1/2010
• Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma  
  Blum KA, Hamadani M, Phillips GS, Lozanski G, Johnson AJ, Lucas DM, Smith LL, Baiocchi RA, Lin TS, Porcu P, Devine SM, Byrd JC, Leukemia & Lymphoma, 1/1/2009
• Join now to see all

Books/Book Chapters

• Non Hodgkins Lymphoma 
  Chapter: Immundeficiency Associated Lymphomas 
  Robert Baiocchi, Pierluigi Porcu, Thomas GrossEditors: James Armitage.Lippincott Williams & Wilkins, Philadelphia, PA2009

Abstracts/Posters

• Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...
  Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma
  Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Targeting Hypersumoylation in Mantle Cell Lymphoma
  Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Restoring Functional Deficits in Older Adults with Hematologic Malignancy
  Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatm...
  Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803...
  Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• PRMT5 Is a Key Epigenetic Regulator That Promotes Transcriptional Activation in Mantle Cell Lymphoma By Regulating the Lysine Methyltransferase SETD7 and MLL1 Activity
  Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Targeting Hypersumoylation in Mantle Cell Lymphoma
  Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
  Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Identifying and Targeting Cytotoxic Tumor-Associated Macrophages in Epstein-Barr Virus-Driven Lymphoproliferative Disease
  Patton JT, Mitchell ML, Pan L, Kinghorn AD, Grever M, Lucas DM, Baiocchi RA, Blood, ASH Annual Meeting, 1/6/2014
• Chung J, Karkhanis V, Sif S, Baiocchi RA, Blood, ASH Annual Meeting, 1/6/2014
• Expression of PRMT5 in B-Cell Chronic Lymphocytic Leukemia and Its Significance in Disease Progression and Richter's Transformation
  El-Gamal D, LaFollette TD, Lai H, Chenglong L, Sampath D, Lehman A, Yu L, Byrd JC, Baiocchi RA, Lapalombella R, Blood, ASH Annual Meeting, 1/1/2014
• High Expression of PRMT5 and Cyclin D1 is associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16 status
  Kumar B, Cipolla MJ, Brown NV, Wakely PE, Yan F, Schmitt AC, Kumar P, Baiocchi RA, Teknos TN, Old M., ASTRO Annual Meeting, 1/1/2014
• Prognostic implications, predictive value and latency analysis of Epstein-Bar virus (EBV) DNA in advanced stage cutaneous T-cell lymphoma (AS-CTCL)
  Haverkos BM, Hemminger J, Geyer SM, Bingman A, VanDuesen K, Lustberg M, Wong H. Gru A. Ambinder R, Baiocchi RA, Porcu P, Clin Oncol, ASCO Meeting, 1/1/2014
• Poor Prognostic Effect of CD5 Positivity for Patients with Diffuse Large B-Cell Lymphoma: Results from a Retrospective Single Institution Analysis
  Alinari L, Gru A, Quinion C, Huang Y, Jones JA, Devine SM, Maddocks KJ, Christian B, Baiocchi RA, Blum KA, Blood, ASH Annual Meeting, 1/1/2014
• The Epstein - Barr virus Lytic Protein BZLF1 As a Candidate Target Antigen for Vaccine Development
  Hartlage AS, Liu T, Patton JT, Garman SL, Zhang X, Kurt H, Lozanski G, Lustberg ME, Caligiuri MA, Baiocchi RA, Blood, ASH Annual Meeting, 1/1/2014
• Determination of Optimal Target Antigen and Immune Modulatory Approaches to Improve and Standardize Epstein-Barr Virus-Specific Adoptive T Cell Therapy
  Mitchell ML, Patton JT, O'Donnell L, Baiocchi RA, Blood, ASH Annual Meeting, 1/1/2014
• Epstein-Barr Virus Kinase-Targeted Therapy for Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder
  Dugan J, Haverkos BM, Martin LK, Martin MF, Lustberg ME, Patton JT, Nuovo G, Yan F, Cavaliere R, Kenney SC, Fingeroth J, Lozanski G, Ramos JC, Porcu P, Caligiuri MA, B..., Blood, ASH Annual Meeting, 1/1/2014
• Protein Arginine Methyltransferase 5 Directly Targets and Epigenetically Silences microRNAs miR33b and miR96 to Support Constitutive Cyclin D1 Activity in Non-Hodgkin’...
  Karkhanis V, Elemento O, Di Liberto M, Chen-Kiang S, Sif S, Baiocchi RA, Blood, ASH Annual Meeting, 1/1/2014
• Silvestrol Modulates Indirect Anti-Tumor Activity and Potentiates Immune Response to Epstein-Barr Virus-Driven Lymphoproliferative Disease
  Patton JT, Hartlage AS, Pan L, Lustberg ME, Drohan CM, Martin MF, Kinghorn AD, Caligiuri MA, Grever MR, Lucas DM, Baiocchi RA, Blood, ASH Annual Meeting, 1/1/2013
• Targeting The PRMT5 Enzyme To Induce -Globin Gene Derepression In Sickle Cell Anemia
  Roach N, Cannon M, El-Gamal D, Desai PC, Kraut EH, Bradner JE, Lapalombella, Baiocchi RA, Blood, ASH Annual Meeting, 1/1/2013
• Developing a first in class of drug to inhibit protein arginine Methyltransferase 5 (PRMT5) enzyme dysregulation in glioblastoma multiforme
  Yan F, Gordon K, Mahasenan K, Lustberg M, Alinari L, Kaur B, Li C, Baiocchi RA, AACR Annual Meeting, Washington, D.C., 1/1/2013
• Preclinical and Pharmacological Activities of Protein Arginine Methyltransferase 5(PRMT5) Enzyme Inhibition in Acute Myeloid Leukemia
  Tarighat SS, Radomska H, Lai H, Mahasenan K, Perrotti D, Garzon R, Caligiuri M, Li C, Blum W, Marcucci G, Baiocchi RA, AACR Annual Meeting, Washington, D.C., 1/1/2013
• Complete Response (CR) to Induction Therapy in Patients (pts) with Myc+ and Double Hit Non-Hodgkin's Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survi...
  Cohen JB, Geyer S, Lozanski G, Zhao X, Heerema NA, Jones JA, Porcu P, Christian B, Baiocchi RA, Maddocks K, Flynn JM, Devine SM, Blum KA, Blood, ASH Annual Meeting, 1/1/2012
• Toxicity in patients (pts) age 65 or older with dose-adjusted REPOCH (DA-REPOCH) for untreated diffuse large B-cell lymphoma (DLBCL)
  Stephens DM, Ruppert AS, Christian B, Jones JA, Flynn JM, Porcu P, Baiocchi RA, Byrd JC, Dotson EK, Crawford BS, Blum KA, Cancer Res, ASCO Meeting, 1/1/2012
• Join now to see all

Lectures

• PRMT5 Is Upregulated in Activated T Cells and Is a Novel Therapeutic Target for Acute Gvhd 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Post graduate career options for the physician scientist 
  Chicago, IL - 1/26/2015
• Targeting Histone Methyltransferases and Demethylases track 
  Boston, MA - 1/24/2015
• Lead Optimization of Novel Drugs to Target PRMT5 in Cancer 
  Columbus, OH - 1/10/2015
• Targeting PRMT5 Expression in Diffuse Large B cell and Mantle Cell Lymphoma 
  New York, NY - 1/8/2015
• Viral Oncogenesis and Immunology 
  San Diego, CA - 1/5/2015
• Developing a National Reputation as a Basic/Translational Scientist 
  Columbus, OH - 1/13/2014
• Tumor Immunology for the non-Immunologist 
  San Diego, CA - 1/5/2014
• Clinical Applications of Immunology in Blood Cancers 
  San Diego, CA - 1/5/2014
• Preclinical and Pharmacological Activities of Protein Arginine Methyltransferase 5(PRMT5) Enzyme Inhibition in Acute Myeloid Leukemia 
  Washington, D.C. - 1/1/2013
• Developing a first in class of drug to inhibit protein arginine Methyltransferase 5 (PRMT5) enzyme dysregulation in glioblastoma multiforme 
  Washington, D.C. - 1/1/2013
• PRMT5 Inhibition induces Death of Lymphoma Cells through Reactivation of the Retinoblastoma Tumor Suppressor Pathway and Silencing of the PRC2 Complex 
  Atlanta, GA - 1/1/2013
• Developing a novel class of epigenetic drug to target PRMT5 in cancer 
  Columbus, OH - 1/1/2013
• HIV Associated Malignancies 
  Columbus, OH - 1/30/2012
• Vaccine Strategies for Preventing EBV-associated Diseases 
  Houston, TX - 1/30/2012
• Management of A Typical HUS 
  1/29/2012
• HIV Related Malignancies 
  Columbus, OH - 1/27/2012
• Developing a new class of drug to target PRMT5 in Cancer 
  Columbus, OH - 1/23/2012
• HIV-associated Lymphomas 
  Columbus, OH - 1/21/2012
• Identification and Use of Compounds to Inhibit PRMT5 Ensyme Activity for Cancer Therapeutics 
  1/21/2012
• Translating Basic Science Observations to Cancer Drug Development 
  Columbus, OH - 1/18/2012
• HIV/AIDS and Cancer 
  Columbus, OH - 1/9/2012
• Impact of an Educational Initiative on Minority Volunteer Perceptions of Clinical Trials 
  Columbus, OH - 1/7/2012
• Applying a Research Agenda to the AMC Patient Navigator Initiative, Aids Malignancy Consortium 
  Los Angeles, CA - 1/28/2011
• Immune Deficiency in Cancer 
  1/21/2011
• Join now to see all

Other

• It’s All About Health 
  Baiocchi RA, Show Joy 106.3
  1/5/2011
• OSU James Care East Expansion 
  Baiocchi RA, Show Joy 106.3
  1/5/2011